The Los Angeles Post
U.S. World Business Lifestyle
Today: April 16, 2025
Today: April 16, 2025

Gilead quarterly results beat Street estimates as profit up on lower taxes

FILE PHOTO: Gilead Sciences Inc pharmaceutical company is seen during the outbreak of the coronavirus disease (COVID-19), in California
April 26, 2024
Deena Beasley - Reuters

By Deena Beasley

(Reuters) - Drugmaker Gilead Sciences on Tuesday said third-quarter sales were little changed from a year earlier, but earnings rose 21% due mainly to lower taxes.

The Foster City, California-based company reported a quarterly profit of $2.29 per share excluding items, on total revenue of $7.1 billion, up from $1.90 a share on revenue of just over $7 billion in the year-ago quarter.

Wall Street analysts had expected an adjusted profit of $1.92 per share on revenue of $6.8 billion, according to LSEG data.

Sales of HIV drug Biktarvy rose 12% to $3.1 billion, which was in line with analysts' estimates. Sales of COVID drug Veklury fell 31% to $636 million, but still came in well above Wall Street expectations of $363 million.

Oncology sales rose 33% to $769 million.

"We are seeing strong growth in our core base business, driven by Biktarvy in HIV and Trodelvy in cancer," Gilead CEO Daniel O'Day said in an interview.

He noted that Gilead will be announcing results from several pivotal-stage clinical trials next year, including Trodelvy as a first-line treatment for lung cancer and oral antiviral obeldesivir as a treatment for COVID.

Gilead said its effective tax rate for the third quarter dropped to 6.3% from 26.6% for the same period in 2022, primarily due to a decrease in tax reserves related to a settlement with the U.S. Internal Revenue Service for prior tax years.

For 2024, Gilead said it continues to expect a tax rate of 16% percent.

Gilead raised its full-year forecast for adjusted earnings and now expects $6.65 to $6.85 per share, up from $6.45 to $6.80. The company also increased its 2023 revenue estimate to a range of $26.7 billion to $26.9 billion from a previous forecast of $26.3 billion to $26.7 billion.

(Reporting By Deena Beasley; Editing by Bill Berkrot)

Related Articles

Trump tariff threats prompt some drugmakers to expedite shipments to US Thermo Fisher buys Solventum's purification and filtration business for $4.1 billion Biogen expects lower 2025 profit as multiple sclerosis drugs face fierce competition Novo Nordisk defends next-gen obesity drug CagriSema, details new trial
Share This

Popular

Business|Economy|Political|US

Americans likely rushed to shop in March ahead of Trumpโ€™s tariffs, but economists say that boost wonโ€™t last

Americans likely rushed to shop in March ahead of Trumpโ€™s tariffs, but economists say that boost wonโ€™t last
Business|Economy|Europe|Finance

UK house prices rose by most in over two years in February, official data shows

UK house prices rose by most in over two years in February, official data shows
Asia|Business|Economy|Political

BOJ to cut growth forecast as US tariffs hit, sources say

BOJ to cut growth forecast as US tariffs hit, sources say
Business|Crime|Europe|Technology

Google faces 5 billion pound UK lawsuit for abusing dominance in online search

Google faces 5 billion pound UK lawsuit for abusing dominance in online search

Economy

Business|Economy|Europe|Technology

Ferrari will continue to invest in petrol, hybrid and EV powetrains, CEO says

Ferrari will continue to invest in petrol, hybrid and EV powetrains, CEO says
Business|Economy|Europe|Finance|Political

Central Europe cannot expect big boost from German fiscal expansion, S&P says

Central Europe cannot expect big boost from German fiscal expansion, S&P says
Asia|Business|Economy|Political|World

China's Xi calls for UN, multilateral systems to be upheld on Southeast Asia trip

China's Xi calls for UN, multilateral systems to be upheld on Southeast Asia trip
Business|Economy|Europe|Finance

Euro zone current account surplus narrowed in February

Euro zone current account surplus narrowed in February

Access this article for free.

Already have an account? Sign In